GlobeNewswire by notified

Oxurion Announces Interim Analysis for KALAHARI Trial

Share

Interim Analysis for KALAHARI trial planned by Year-End 2022 withFull Top-Line Data Expected inSecond halfof 2023

Leuven, BELGIUM, Boston, MA, US November 18, 2022 10:00 PM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced it is planning an interim analysis of at least 25% of the patients for the KALAHARI Phase 2, Part B clinical trial. Results of the interim analysis are expected by year-end 2022 and full top-line data from the trial is now expected in the second half of 2023.

The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) candidate, THR-149, as a potential treatment for patients who respond suboptimally to anti-VEGF standard of care for treatment of diabetic macular edema (DME). The Phase 2 KALAHARI study is a two-part, randomized, prospective, multi-center study assessing multiple injections of THR-149 in DME patients who have previously shown a suboptimal response to anti-VEGF therapy. Part B follows Part A of the study, in which three dose levels of THR-149 (0.005mg, 0.022mg and 0.13mg), were each administered in three monthly IVT injections, were evaluated in order to select the best dose for Part B of the study.

High-level Month 3 data from Part A of the KALAHARI trial was first presented in October 2021 and demonstrated that in the eight patients who received the highest dose of THR-149, a mean BCVA gain of 6.1 letters at Month 3, the primary endpoint, was observed. A post-hoc analysis of an OCT (Optical Coherence Tomography) biomarker assessment, was performed by the masked central reading center in February 2022. The masked reading center identified two subjects with abnormalities at baseline, which could impact responsiveness to any medical treatment. Excluding these two subjects resulted in an improvement in mean BCVA of 9.3 letters at Month 3 that was sustained until Month 6, the end of the trial. The six-month data also demonstrated THR-149’s attractive safety profile and its ability to stabilize the Central Subfield Thickness (CST). The learnings from the Part A data were incorporated into Part B through an amended study design. More information can be found here: NCT04527107

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michael Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com

US
Conway Communications
Beth Kurth
bkurth@conwaycommsir.com





ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
Chris.Brinzey@westwicke.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Camposol Holding PLC - Invitation to the Third Quarter 2022 Financial Results Presentation26.11.2022 00:03:54 CET | Press release

Camposol Holding PLC will announce its financial results of the third quarter of 2022 on Tuesday, November 29, at 13:00 (GMT -5). The call will be conducted by our CEO, Jose Antonio Gomez - Bazan. Use the following link to register and participate in the call: Participant Registration URL: https://register.vevent.com/register/BI64a53cb1ca2843bdb219d095254b1c94 Participants are advised to log on to the service and check their settings a few minutes before the conference call begins. About CAMPOSOL CAMPOSOL is a multinational company that provides families around the world with fresh and healthy food. We have operations in Chile, Colombia, Mexico, Peru, and Uruguay, commercial offices in North America, Europe, and Asia, a corporate office in Costa Rica, and trusted relationships with the main supermarkets worldwide, as well as customers in more than 40 countries. We are involved in the harvest, processing, and marketing of high-quality agricultural products such as avocados, blueberries,

Cool Company Ltd. - Granting of Share Options and Restricted Stock Units to Primary Insiders and Mandatory Notifications of Trade25.11.2022 22:42:08 CET | Press release

Bermuda, November 25, 2022: Reference is made to the stock exchange notice from Cool Company Ltd. (“CoolCo” or the “Company”) on November 25, 2022 announcing that the board of directors of the Company (the “Board”) had resolved to implement a long-term incentive program for employees, management and board members of the Company and its affiliates (the "LTIP"). Pursuant to the LTIP, the Board has resolved to grant options over a total number of 1,237,423 shares and 115,000 restricted stock units to employees, management and board members of the Company (equivalent to approximately 2.25% and 0.2% of the Company's share capital, respectively), of which 11,507 restricted stock units and options over a total number of 742,454 shares were granted to primary insiders of the Company (equivalent to approximately 0.02% and 1.38% of the Company's share capital, respectively). Each share option, when exercised, carries the right to acquire one share in CoolCo, giving the right to acquire up to in

Cool Company Ltd. - Approval of Long-Term Incentive Plan25.11.2022 20:13:34 CET | Press release

Bermuda, November 25, 2022: The board of directors (the “Board”) of Cool Company Ltd. (“CoolCo” or the “Company”) has resolved to implement a long-term incentive plan (the “LTIP”) for employees, management and board members of the Company and its affiliates. The overall purpose of the LTIP is to promote the success of the Company for the benefit of its shareholders, by providing a framework for the retention and incentivization of employees using the Company’s equity and thereby aligning their interests with the Company and its affiliates. The LTIP provides for the grant of equity awards, with the intention being for the initial awards to be granted as options (“Options”) and restricted stock units (the “RSUs”), as further detailed below. Shares used under the LTIP are expected to be covered by the Board's authorization to issue authorized and unissued shares in connection with a grant of warrants, options or other securities with rights to convert such securities into shares of the Co

Fingerprint Cards AB (publ) publishes the final outcome of the rights issue25.11.2022 20:10:00 CET | Press release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS), AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THE PRESS RELEASE. The final outcome in Fingerprint Cards AB’s (publ) (“Fingerprints” or the “Company”) SEK 300 million rights issue of B-units (“B-units”), consisting of new B-shares and warrants (the “Fully Guaranteed Rights Issue”) shows that 16,851,001 B-units, corresponding to approximately 84.9 per cent of the B-units offered, have been subscribed for with support of unit subscription rights. The remaining 2,987,938 B-units have been subscribed for without support of unit subscription rights, corres

Fingerprint Cards AB (publ) offentliggör slutligt utfall i företrädesemissionen25.11.2022 20:10:00 CET | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA (INKLUSIVE DESS TERRIRTORIER OCH BESITTNINGAR), AUSTRALIEN, JAPAN, KANADA, HONGKONG, NYA ZEELAND, SINGAPORE ELLER SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA OLAGLIGT ELLER KRÄVA REGISTERING ELLER ANDRA ÅTGÄRDER ENLIGT GÄLLANDE LAG. ANDRA RESTRIKTIONER ÄR TILLÄMPLIGA. VÄNLIGEN SE AVSNITTET "VIKTIG INFORMATION" I SLUTET AV DETTA PRESSMEDDELANDE. Det slutliga utfallet i Fingerprint Cards AB:s (publ) (“Fingerprints” eller “Bolaget”) företrädesemission av B-units om 300 miljoner kronor (”B-units”), bestående av nya B-aktier och teckningsoptioner (den ”Fullt Garanterade Företrädesemissionen”) visar att 16 851 001 B-units, motsvarande cirka 84,9 procent av erbjudna B-units, har tecknats med stöd av uniträtter. Återstående 2 987 938 B-units tecknades utan stöd av uniträtter, motsvarande cirka 15,1 procent av erbjudna B-units. Tillsammans utgör te